Advertisement

NK Cells in Autoimmune and Inflammatory Diseases

  • Nicolas Schleinitz
  • Nassim Dali-Youcef
  • Jean-Robert Harle
  • Jacques Zimmer
  • Emmanuel AndresEmail author
Chapter

Abstract

The evidence of NK cell implication in human diseases has initially been shown for antiviral immunity and tumor surveillance. Nowadays, increased attention is being paid to the aspect of NK cells and innate immunity in studies on autoimmune diseases. However, despite a growing knowledge on NK cell function and regulation, their role in human autoimmune disease still remains controversial. In animal models, studies of NK cells have shown conflicting results toward a disease-promoting or disease-protective role. Similarly, in human diseases, available data suggest an unequivocal role of NK cells. Yet, the understanding of NK cell implication in human diseases is far from being achieved. We review here the current knowledge on NK cell biology in human autoimmune and inflammatory diseases and discuss their possible mechanisms of action in these complex pathologies.

Keywords

Systemic Lupus Erythematosus Natural Killer Cell Systemic Lupus Erythematosus Patient Idiopathic Inflammatory Myopathy Natural Killer Cell Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Johansson S, Berg L, Hall H, Hoglund P (2005) NK cells: elusive players in autoimmunity. Trends Immunol 26(11):613–618CrossRefPubMedGoogle Scholar
  2. 2.
    Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M et al (2001) Human natural killer cell receptors and co-receptors. Immunol Rev 181:203–214CrossRefPubMedGoogle Scholar
  3. 3.
    Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR (2005) Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 141(1):165–173CrossRefPubMedGoogle Scholar
  4. 4.
    Vitale C, Chiossone L, Cantoni C, Morreale G, Cottalasso F, Moretti S et al (2004) The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. Eur J Immunol 34(11):3028–3038CrossRefPubMedGoogle Scholar
  5. 5.
    Pascual V, Banchereau J, Palucka AK (2003) The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 15(5):548–556CrossRefPubMedGoogle Scholar
  6. 6.
    James JA, Harley JB, Scofield RH (2001) Role of viruses in systemic lupus erythematosus and Sjogren syndrome. Curr Opin Rheumatol 13(5):370–376CrossRefPubMedGoogle Scholar
  7. 7.
    Moins-Teisserenc HT, Gadola SD, Cella M, Dunbar PR, Exley A, Blake N et al (1999) Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet 354(9190):1598–1603CrossRefPubMedGoogle Scholar
  8. 8.
    Markel G, Mussaffi H, Ling KL, Salio M, Gadola S, Steuer G et al (2004) The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 103(5):1770–1778CrossRefPubMedGoogle Scholar
  9. 9.
    Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11(7):237–244CrossRefPubMedGoogle Scholar
  10. 10.
    de la Salle H, Zimmer J, Fricker D, Angenieux C, Cazenave JP, Okubo M et al (1999) HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J Clin Invest 103(5):R9–R13CrossRefGoogle Scholar
  11. 11.
    Handgretinger R, Geiselhart A, Moris A, Grau R, Teuffel O, Bethge W et al (1999) Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 340(4):278–284CrossRefPubMedGoogle Scholar
  12. 12.
    Lamy T, Loughran TP Jr (2003) Clinical features of large granular lymphocyte leukemia. Semin Hematol 40(3):185–195CrossRefPubMedGoogle Scholar
  13. 13.
    Loughran TP Jr (1993) Clonal diseases of large granular lymphocytes. Blood 82(1):1–14PubMedGoogle Scholar
  14. 14.
    Pascal V, Schleinitz N, Brunet C, Ravet S, Bonnet E, Lafarge X et al (2004) Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions. Eur J Immunol 34(10):2930–2940CrossRefPubMedGoogle Scholar
  15. 15.
    Zambello R, Falco M, Della Chiesa M, Trentin L, Carollo D, Castriconi R et al (2003) Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood 102(5):1797–1805CrossRefPubMedGoogle Scholar
  16. 16.
    Scquizzato E, Teramo A, Miorin M, Facco M, Piazza F, Noventa F et al (2007) Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia 21(5):1060–1069PubMedGoogle Scholar
  17. 17.
    Tefferi A (1996) Chronic natural killer cell lymphocytosis. Leuk Lymphoma 20(3–4): 245–248CrossRefPubMedGoogle Scholar
  18. 18.
    Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL (1994) Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood 84(8):2721–2725PubMedGoogle Scholar
  19. 19.
    Lima M, Almeida J, Montero AG, Teixeira Mdos A, Queiros ML, Santos AH et al (2004) Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol 165(4):1117–1127PubMedGoogle Scholar
  20. 20.
    Trowsdale J, Barten R, Haude A, Stewart CA, Beck S, Wilson MJ (2001) The genomic context of natural killer receptor extended gene families. Immunol Rev 181:20–38CrossRefPubMedGoogle Scholar
  21. 21.
    Barrow AD, Trowsdale J (2008) The extended human leukocyte receptor complex: diverse ways of modulating immune responses. Immunol Rev 224(1):98–123CrossRefPubMedGoogle Scholar
  22. 22.
    Uhrberg M, Parham P, Wernet P (2002) Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 54(4):221–229CrossRefPubMedGoogle Scholar
  23. 23.
    Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B et al (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7(6):753–763CrossRefPubMedGoogle Scholar
  24. 24.
    Middleton D, Meenagh A, Moscoso J, Arnaiz-Villena A (2008) Killer immunoglobulin receptor gene and allele frequencies in Caucasoid, Oriental and Black populations from different continents. Tissue Antigens 71(2):105–113CrossRefPubMedGoogle Scholar
  25. 25.
    Ruggeri L, Aversa F, Martelli MF, Velardi A (2006) Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 214:202–218CrossRefPubMedGoogle Scholar
  26. 26.
    Boyton RJ, Altmann DM (2007) Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 149(1):1–8CrossRefPubMedGoogle Scholar
  27. 27.
    Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE et al (2004) Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 50(5):1561–1565CrossRefPubMedGoogle Scholar
  28. 28.
    Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD (2007) KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 69(Suppl 1):106–108CrossRefPubMedGoogle Scholar
  29. 29.
    van der Slik AR, Alizadeh BZ, Koeleman BP, Roep BO, Giphart MJ (2007) Modelling KIR-HLA genotype disparities in type 1 diabetes. Tissue Antigens 69(Suppl 1):101–105CrossRefPubMedGoogle Scholar
  30. 30.
    van der Slik AR, Koeleman BP, Verduijn W, Bruining GJ, Roep BO, Giphart MJ (2003) KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 52(10):2639–2642CrossRefPubMedGoogle Scholar
  31. 31.
    Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M (2004) Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 173(7):4273–4276PubMedGoogle Scholar
  32. 32.
    Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J et al (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169(6):2818–2822PubMedGoogle Scholar
  33. 33.
    Parham P (2004) NK cells and trophoblasts: partners in pregnancy. J Exp Med 200(8): 951–955CrossRefPubMedGoogle Scholar
  34. 34.
    Varla-Leftherioti M, Spyropoulou-Vlachou M, Niokou D, Keramitsoglou T, Darlamitsou A, Tsekoura C et al (2003) Natural killer (NK) cell receptors' repertoire in couples with recurrent spontaneous abortions. Am J Reprod Immunol 49(3):183–191CrossRefPubMedGoogle Scholar
  35. 35.
    Varla-Leftherioti M (2005) The significance of the women's repertoire of natural killer cell receptors in the maintenance of pregnancy. Chem Immunol Allergy 89:84–95CrossRefPubMedGoogle Scholar
  36. 36.
    Kwak JY, Beaman KD, Gilman-Sachs A, Ruiz JE, Schewitz D, Beer AE (1995) Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Am J Reprod Immunol 34(2):93–99PubMedGoogle Scholar
  37. 37.
    Anfossi N, Doisne JM, Peyrat MA, Ugolini S, Bonnaud O, Bossy D et al (2004) Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol 173(12):7223–7229PubMedGoogle Scholar
  38. 38.
    Saruhan-Direskeneli G, Uyar FA, Cefle A, Onder SC, Eksioglu-Demiralp E, Kamali S et al (2004) Expression of KIR and C-type lectin receptors in Behcet's disease. Rheumatology 43(4):423–427CrossRefPubMedGoogle Scholar
  39. 39.
    Takeno M, Shimoyama Y, Kashiwakura J, Nagafuchi H, Sakane T, Suzuki N (2004) Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behcet's disease. Rheumatol Int 24(4):212–216CrossRefPubMedGoogle Scholar
  40. 40.
    Middleton D, Meenagh A, Sleator C, Gourraud PA, Ayna T, Tozkir H et al (2007) No association of KIR genes with Behcet's disease. Tissue Antigens 70(5):435–438CrossRefPubMedGoogle Scholar
  41. 41.
    Chan AT, Kollnberger SD, Wedderburn LR, Bowness P (2005) Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 52(11):3586–3595CrossRefPubMedGoogle Scholar
  42. 42.
    Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM et al (2000) Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol 165(2):1138–1145PubMedGoogle Scholar
  43. 43.
    Capraru D, Muller A, Csernok E, Gross WL, Holl-Ulrich K, Northfield J et al (2008) Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis. Clin Immunol 127(2):144–150CrossRefPubMedGoogle Scholar
  44. 44.
    Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N et al (2007) CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132(7):2346–2358CrossRefPubMedGoogle Scholar
  45. 45.
    Schleinitz N, Cognet C, Guia S, Laugier-Anfossi F, Baratin M, Pouget J et al (2008) Expression of the CD85j (leukocyte Ig-like receptor 1, Ig-like transcript 2) receptor for class I major histocompatibility complex molecules in idiopathic inflammatory myopathies. Arthritis Rheum 58(10):3216–3223CrossRefPubMedGoogle Scholar
  46. 46.
    Ferlazzo G (2008) Isolation and analysis of human natural killer cell subsets. Methods Mol Biol 415:197–213CrossRefPubMedGoogle Scholar
  47. 47.
    Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA et al (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172(3):1455–1462PubMedGoogle Scholar
  48. 48.
    Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, et al (2007) Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 110(7):2484–2493Google Scholar
  49. 49.
    Ferlazzo G, Morandi B, D'Agostino A, Meazza R, Melioli G, Moretta A et al (2003) The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol 33(2):306–313CrossRefPubMedGoogle Scholar
  50. 50.
    Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294(5546):1540–1543CrossRefPubMedGoogle Scholar
  51. 51.
    Ghiringhelli F, Menard C, Martin F, Zitvogel L (2006) The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 214:229–238CrossRefPubMedGoogle Scholar
  52. 52.
    Trzonkowski P, Szmit E, Mysliwska J, Mysliwski A (2006) CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin Immunol 119(3):307–316CrossRefPubMedGoogle Scholar
  53. 53.
    Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N et al (2005) CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202(8):1075–1085CrossRefPubMedGoogle Scholar
  54. 54.
    Costantino CM, Baecher-Allan CM, Hafler DA (2008) Human regulatory T cells and autoimmunity. Eur J Immunol 38(4):921–924CrossRefPubMedGoogle Scholar
  55. 55.
    Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z et al (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27CrossRefPubMedGoogle Scholar
  56. 56.
    Liu R, Van Kaer L, La Cava A, Price M, Campagnolo DI, Collins M et al (2006) Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol 176(9):5247–5254PubMedGoogle Scholar
  57. 57.
    Stern JN, Keskin DB, Barteneva N, Zuniga J, Yunis EJ, Ahmed AR (2008) Possible role of natural killer cells in pemphigus vulgaris – preliminary observations. Clin Exp Immunol 152(3):472–481CrossRefPubMedGoogle Scholar
  58. 58.
    Takahashi H, Amagai M, Tanikawa A, Suzuki S, Ikeda Y, Nishikawa T et al (2007) T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris. J Invest Dermatol 127(2):324–330CrossRefPubMedGoogle Scholar
  59. 59.
    Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, et al (2000) Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity? Lupus 9(5):333–337Google Scholar
  60. 60.
    Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P (1993) Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 2(4):227–231CrossRefPubMedGoogle Scholar
  61. 61.
    Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K et al (1996) A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 23(1):171–177PubMedGoogle Scholar
  62. 62.
    Tomasello E, Vivier E (2005) KARAP/DAP12/TYROBP: three names and a multiplicity of biological functions. Eur J Immunol 35(6):1670–1677CrossRefPubMedGoogle Scholar
  63. 63.
    Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Karre K, et al (2009) Increased proportion of CD56(bright) natural killer cells in active and inactive systemic lupus erythematosus. Immunology 125(1): 140–146Google Scholar
  64. 64.
    Izumi Y, Ida H, Huang M, Iwanaga N, Tanaka F, Aratake K et al (2006) Characterization of peripheral natural killer cells in primary Sjogren's syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med 147(5):242–249CrossRefPubMedGoogle Scholar
  65. 65.
    Ercole LP, Malvezzi M, Boaretti AC, Utiyama SR, Rachid A (2003) Analysis of lymphocyte subpopulations in systemic sclerosis. J Invest Allergol Clin Immunol 13(2):87–93Google Scholar
  66. 66.
    Horikawa M, Hasegawa M, Komura K, Hayakawa I, Yanaba K, Matsushita T et al (2005) Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J Invest Dermatol 125(4):731–737CrossRefPubMedGoogle Scholar
  67. 67.
    Majorczyk E, Pawlik A, Luszczek W, Nowak I, Wisniewski A, Jasek M et al (2007) Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Genes Immun 8(8):678–683CrossRefPubMedGoogle Scholar
  68. 68.
    Yen JH, Lin CH, Tsai WC, Wu CC, Ou TT, Hu CJ et al (2006) Killer cell immunoglobulin-like receptor gene's repertoire in rheumatoid arthritis. Scand J Rheumatol 35(2):124–127CrossRefPubMedGoogle Scholar
  69. 69.
    Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC, Bruges Armas J, Suarez-Alvarez B, Pruneda L et al (2006) Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther 8(4):R101Google Scholar
  70. 70.
    Jiao YL, Ma CY, Wang LC, Cui B, Zhang J, You L et al (2008) Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease. J Clin Immunol 28(4):343–349CrossRefPubMedGoogle Scholar
  71. 71.
    Cameron AL, Kirby B, Griffiths CE (2003) Circulating natural killer cells in psoriasis. Br J Dermatol 149(1):160–164CrossRefPubMedGoogle Scholar
  72. 72.
    Jones DC, Edgar RS, Ahmad T, Cummings JR, Jewell DP, Trowsdale J et al (2006) Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun 7(7):576–582CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Nicolas Schleinitz
    • 1
  • Nassim Dali-Youcef
    • 2
  • Jean-Robert Harle
    • 1
  • Jacques Zimmer
    • 3
  • Emmanuel Andres
    • 4
    Email author
  1. 1.Department of Internal MedicineCHRU de MarseilleMarseilleFrance
  2. 2.Laboratory of general and specialized BiochemistryHôpitaux Universitaires de Strasbourg and Department of Biochemistry, Faculty of MedicineStrasbourgFrance
  3. 3.Laboratoire d’Immunogénétique-AllergologieCentre de Recherche Public de la Santé (CRP-Santé) de LuxembourgLuxembourgLuxembourg
  4. 4.Service de Médecine InterneDiabète et Maladies Métaboliques, Clinique Médicale B, Hôpital Civil – Hôpitaux Universitaires de Strasbourg, 1 porte de l’HôpitalStrasbourg CedexFrance

Personalised recommendations